Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

Summary T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma a...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2007-11, Vol.139 (3), p.425-428
Main Authors: O'Connor, Owen A., Hamlin, Paul A., Portlock, Carol, Moskowitz, Craig H., Noy, Ariela, Straus, David J., MacGregor‐Cortelli, Barbara, Neylon, Ellen, Sarasohn, Debra, Dumetrescu, Otila, Mould, Diane R., Fleischer, Martin, Zelenetz, Andrew D., Sirotnak, Frank, Horwitz, Steven
Format: Article
Language:English
Subjects:
Adult
Aged
Aminopterin - analogs & derivatives
Aminopterin - metabolism
Aminopterin - therapeutic use
antifolate
Antineoplastic Agents - metabolism
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Female
Folic Acid Antagonists - metabolism
Folic Acid Antagonists - therapeutic use
Hematologic and hematopoietic diseases
Humans
Lymphoma, B-Cell - drug therapy
Lymphoma, T-Cell - diagnostic imaging
Lymphoma, T-Cell - drug therapy
Male
Medical sciences
Membrane Transport Proteins - metabolism
Middle Aged
Positron-Emission Tomography
pralatrexate
reduced folate carrier
Treatment Failure
Treatment Outcome
T‐cell lymphoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B‐cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2007.06658.x